OpRegen

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Age-Related Macular DegenerationGeographic Atrophy

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

1

Eylea

Regeneron

Phase 3

442

Lucentis

Roche

Phase 3

643

Vabysmo

Roche

Phase 3

134

Beovu

Novartis

Phase 3

105

Macugen

Pfizer

Phase 3

66

Avastin

BBio-Thera Solutions

Phase 3

187

Retaane

AAlcon Research

Phase 3

58

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

29

Kenalog

BBausch Health Americas, Inc.

Phase 3

210

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Active, not recruiting·Roche·Phase 1/2·NCT02286089·24 enrolled

Geographic Atrophy1 trial

A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting·Roche·Phase 2·NCT05626114·60 enrolled

Details

Drug Info

Related News